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A recent surge of reports from pediatricians in
industrialized countries indicates that many
girls are presenting with secondary sex charac-
teristics at a younger age than has previously
been considered normal (Herman-Giddens
et al. 1997, 2001; Papadimitriou 2001). For
example, current medical texts generally state
that only 1% of girls show signs of puberty
(breast development or growth of pubic hair)
before 8 years of age. However, a study by
Herman-Giddens et al. (1997) indicates that a
substantial portion of American girls are pre-
senting with one or both of these characteris-
tics by age seven, and that 1% of girls have one
or both of these pubertal markers by age three.
Studies have also shown that the rate of growth
for children and adolescents in the United
States and other countries is significantly
greater than in previous years (Freedman et al.
2000; Karpati et al. 2002). Some countries
have even recorded an overall increase in ﬁnal
height (Padez 2002), although a recent review
on the phenomenon concluded that the trends
in ﬁnal height and pubertal development are
not strongly connected and that more longitu-
dinal studies are needed for investigators to
understand the short- and long-term conse-
quences of the trends before we can interpret
their importance (Karlberg 2002).
The phenomena of earlier puberty and
increased final height have commonly been
referred to as “the secular trend in growth.” It is
believed that the trend may have been in place
for as many as 150 years in certain parts of the
world (Samaras and Storms 2002), and it has
been attributed largely to better child care—
primarily as a result of improved nutrition,
increased food supply, and improved health
and sanitation services. A second hypothesis is
that in some cases the mechanism of precocious
puberty might involve environmental exposure
to estrogenic endocrine disruptors (Teilmann et
al. 2002). This has been suggested after studies
indicating that a relatively high proportion of
children (primarily girls) who have emigrated
from developing to developed countries suffer
precocious puberty and that their blood serum
contains elevated levels of estrogenic pesticides
(Krstevska-Konstantinova et al. 2001).
Environmental exposures have also been associ-
ated with delayed puberty. Data from the
Third National Health And Nutrition
Examination Survey (NHANES III) supported
a signiﬁcant negative relation between blood
lead levels and delayed attainment of menarche
and pubic hair among U.S. girls 10–16 years of
age (Wu et al. 2003). Among girls 8–18 years
of age in the NHANES III, blood lead concen-
trations were signiﬁcantly associated with delays
in growth and pubertal development (Selevan
et al. 2003). Although these and other exam-
ples provide evidence that endocrine disruptors
may disturb pubertal development, there has
been little research in this area, and therefore
we do not yet have any clear cause–effect
relationships in humans. 
One reason for the confusion surrounding
the secular trend in growth is that puberty is a
complex and multifaceted process that does
not have a single identiﬁable trigger. A large,
longitudinal study such as the National
Children’s Study (NCS 2003) offers an ideal
opportunity to further investigate the causes
of the secular growth phenomenon, as it
would enable researchers to obtain samples
from multiple individuals at multiple time
points of development. This would permit a
thorough characterization of pubertal and
other growth processes. In this way the NCS
also affords an unprecedented and unparal-
leled opportunity to study the true sensitivity
and accuracy of current biomarkers of puber-
tal development, to further characterize and
develop and reﬁne emerging biomarkers, and
to identify previously unknown biomarkers.
Furthermore, the length of the study and the
fact that indicators of pubertal development in
children are unlikely to be measured for at
least 5–10 years provides ample time to
develop and reﬁne emerging biomarkers and
techniques for biomarker identiﬁcation. The
purpose of this review is to discuss current and
emerging biomarkers of male and female
pubertal development that might be of use in a
longitudinal children’s study such as the NCS. 
Biomarkers
The term “biomarker” has been defined in
many ways. For the purposes of this review, a
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The proposed National Children’s Study has helped raise awareness of the issues related to children’s
health and the importance of monitoring the growth and development of children from preconcep-
tion through adulthood. Many genetic predispositions can adversely impact the normal development
process, and various environmental exposures have been linked to adverse reproductive health in
rodent models and a small number of accidental human exposures. To monitor reproductive health
and identify adverse effects at the earliest possible juncture, investigators must develop a network of
biomarkers covering all stages and aspects of reproductive development and function. Biomarkers are
biological indicators that can be measured repeatedly and are informative on one or more aspects of
biological development or function. They can range from the anatomical level down to the molecular
level and may provide information on the nature of an exposure, the effect of an exposure, or the sus-
ceptibility of individuals or populations to the toxic effects of an exposure. In theory, biomarkers can
be used to monitor a wide variety of conditions and responses ranging from abnormal development to
early indicators of late-onset disease. The main stumbling block with this theory has been ﬁnding
appropriate biomarkers for particular conditions and exposures. Such biomarkers must be easily acces-
sible, robust, and sensitive. Ideally, they will be expressed across a large section of the population, and
can be monitored quickly, easily, conveniently, and with minimal cost. In this review, we discuss some
of the current and emerging biomarkers of human pubertal development. Key words: biomarker,
development, human, longitudinal cohort study, puberty. Environ Health Perspect 112:105–112
(2004). doi:10.1289/ehp.6265 available via http://dx.doi.org/ [Online 24 September 2003]biomarker is any biological index capable of
being measured that is associated with or
indicative of a defined biological end point
such as a developmental or disease stage.
Biomarkers can be informative on several dif-
ferent levels: a) Biomarkers of developmental
or disease stage—measurable indices that indi-
cate a specific stage in a normal or disease
development process. These are the focus of
this article as they pertain to puberty.
b) Biomarkers of exposure—measurable
changes in biological appearance or function
that indicate exposure to a particular stimulus,
which may be chemical, biological, or physical
in nature. Such biomarkers may be useful in
identifying potentially toxic exposures.
Biomarkers of exposure need not be a direct
result of the exposure, although in many
examples this is the case. c) Biomarkers of
effect—environmental exposures, either
chemical or physical, that can produce a mul-
titude of effects. These may be systemic or
localized, and measurable at the clinical, cellu-
lar, or molecular level. d) Biomarkers of sus-
ceptibility—it is increasingly recognized that
genetic markers can be used to identify pre-
disposition or increased risk of developing
certain conditions. Some individuals have
genetic makeups that make them more or less
susceptible to developing certain diseases,
whether genetically or environmentally
induced or a combination of both.
Biomarkers can include a variety of meas-
urable targets, including biochemical, molecu-
lar, cellular, genetic, immunological, or
physiological changes. Some of those described
to date include the presence of a parent com-
pound or metabolite (Hecht 2002); prolifera-
tion and differentiation indices (Iatropoulos
and Williams 1996); apoptotic end points
(Samaha et al. 1997); formation of DNA
adducts or damage (Poirier and Weston 1996);
chromosomal abnormalities (Lucas 1997);
micronuclei formation (Schoket et al. 1999);
expression of specific genes (Riggins 2001);
changes in gene expression profile (single or
multiple genes) (Thomas et al. 2001); and
measurement of enzyme activity (Chen et al.
1999), to name but a few. In some cases differ-
ent biomarkers can be used to measure the
same indicator. At the gross, physiological
level, for example, genital or breast size and the
growth of pubic hair can be used to stage
pubertal development. Other biomarkers of
puberty are cellular in nature, including serum
levels of pituitary–gonadal axis hormones and
other proteins.
In the context of a large epidemiologic
study such as the NCS, biomarkers must be
easy to obtain and measure. This means that
they are obtainable with noninvasive or
minimally invasive measures, and that the
assay(s) used to measure the biomarker(s) are
robust, sensitive, and, optimally, adaptable to
a high throughput format. The biomarkers
requiring the least effort to measure are those
apparent in gross anatomy. Perhaps the best
example of this is the use of Tanner scales as
biomarkers of pubertal developmental stage
(Tanner 1962). 
Tanner Scales: Anatomical
Markers for Staging Pubertal
Development 
Puberty is a developmental period associated
with tremendous change. The timing of the
onset of puberty varies among adolescents as
does, most likely, the interval between onset of
pubertal markers. Changes in onset of markers
correlate more strongly with the presence of
secondary sex characteristics than they do with
chronological age (Marshall and Tanner 1969,
1970; Wu et al. 2002). Although recent stud-
ies suggest that differences appear to exist in
the ordering of pubertal development across
different racial groups (de Muinich Keizer and
Mul 2001; Herman-Giddens et al. 1997; Wu
et al. 2002), the order in which secondary sex
characteristics appear and their subsequent
stages of development had previously been
considered to be relatively uniform (Tanner
1986). On the basis of this earlier knowledge
of pubertal development, Tanner (1962)
developed a standard for assessing pubertal
development (sexual maturity scale; SMS) that
has been used widely in clinical practice for
many years. In girls this scale encompasses age
at breast and pubic hair developmental stage
and age at menarche. Not all girls (women)
are able to accurately recall their exact age at
menarche. Investigators have handled such
missing data in a number of ways, either by
substituting the mean age for girls with known
ages, or using grade in school and presumed
chronological age assuming the girl entered
school at 5 years of age and did not skip or
repeat a grade. Other crude proxies of pubertal
development in girls include presence/absence
of axillary hair (Lindgren 1996). Although
there is no direct analogy of age at menarche
for boys, there is a Tanner scale for assessing
pubertal stage in boys. In addition, some
investigators have used proxy markers such as
axillary hair, voice changes, testicular size,
(3–4 mL) or age at ejaculation. It is important
to note that these changes do not occur simul-
taneously but follow growth of the testes and
penis at varying time intervals (Tanner 1986).
With respect to the Tanner method, a
limitation for use in some populations or
under certain circumstances is that it requires
nude children and adolescents to be visually
inspected by a trained clinician for the
appearance of secondary sex characteristics.
The Tanner SMS is often not practical for the
purposes of population-based research, as
many adolescents (and their parents) are
uncomfortable with the idea of being
undressed in the presence of a stranger. Given
this limitation, many investigators have
attempted to develop alternative methods of
obtaining this information. 
Duke and colleagues (1980) were the ﬁrst
to develop a method to determine pubertal
development via self-assessment. Adolescents
were shown sex-specific sets of the SMS
photographs (with accompanying descriptive
phrases developed by the investigators) and
were asked to indicate which photograph in
each series (breast, penis, and pubic hair
growth, as appropriate) most closely resem-
bled their current stage of development.
Participants were also examined and indepen-
dently rated by one of the investigators. There
was considerable agreement between the
assessment of secondary sex characteristics by
adolescent girls and the assessment by investi-
gators, ranging from κ = 0.81 for breast
development to κ = 0.91 for pubic hair distri-
bution. Among males the concordance was
also high, with a kappa coefﬁcient of 0.88 for
penis development and pubic hair distribu-
tion combined. In instances where there was
disagreement between the adolescent and the
investigator, the ratings never differed by
more than one Tanner stage. 
Since the pioneering work of Duke et al.
in 1980, several investigators have evaluated
their approach in other populations. One of
the criticisms of Duke’s work is that the study
population was predominantly white and of
upper socioeconomic status. Neinstein (1982)
set out to test the method in an ethnically
diverse middle-income population. Among
females he found a correlation of 0.86 for
breast development and a correlation of 0.73
for pubic hair distribution. For males he
reported correlations of 0.73 and 0.69 for
penis development and pubic hair distribu-
tion, respectively. The correlation between the
adolescent rating and the physician rating of
overall pubertal development was higher
among females than among males (p < 0.05);
however, there were no signiﬁcant differences
with respect to race or ethnicity. This is an
important finding, as age at puberty mile-
stones are reported in some populations to
vary by race/ethnicity (Wu et al. 2002).
Another concern raised regarding the use
of the method of Duke and colleagues is that it
may not be appropriate for use in adolescents
with mental and/or physical problems. To
address this issue, Hardoff and Tamir (1993)
asked both learning-disabled and non–learn-
ing-disabled adolescents of normal intelligence
to indicate which Tanner photograph most
closely resembled their current stage of pubic
hair development. Among the learning-
disabled adolescents, only 58% were able to
accurately identify their current pubertal stage
(κ = 0.43). Ten percent of learning-disabled
adolescents overestimated their current pubertal
Mini-Monograph | Rockett et al.
106 VOLUME 112 | NUMBER 1 | January 2004 • Environmental Health Perspectivesstage, compared with only 2% of non–learning-
disabled adolescents.
How well can puberty be measured in
subgroups of children with underlying
medical problems that act either directly or
indirectly on the hypothalamus–pituitary–
gonadal (HPG) axis? One answer comes from
studies of children with cystic fibrosis (CF).
Children with CF are often smaller and thin-
ner than those without the disease, a fact that
can lead them to become self-conscious about
their appearance. Boas and colleagues (1995)
compared the accuracy of self-reported puber-
tal development in a sample of both male ado-
lescents with CF and those without the
disease. After being examined by a physician,
the participants were asked to identify which
of the Tanner photographs looked most like
their current stage of development. For pubic
hair they reported kappa coefﬁcients of 0.802
and 0.732 for the adolescents with CF and
those without CF, respectively. Penis develop-
ment was reported less accurately, with a
kappa coefﬁcient of 0.489 for males with CF
and a kappa of 0.345 for those without the
disease. Similarly, Schall and colleagues (2002)
demonstrated that self-assessment of pubertal
status is valid and reliable for use among ado-
lescents with Crohn disease. Among female
adolescents, they reported kappa coefficients
of 0.74 and 0.81 for breast development and
pubic hair distribution, respectively. The
agreement was slightly better among males,
with a kappa coefﬁcient of 0.85 for both penis
development and pubic hair stage.
At approximately the same time that Duke
and associates were working on their self-
assessment method, Morris and Udry (1980)
were developing a similar tool. The method of
Morris and Udry, however, was based on
illustrations made from the original Tanner
photographs. In addition to having short
descriptions under each drawing, they also
asked several general questions regarding
pubertal development, such as “Do the clothes
you wore last year still ﬁt?” Adolescent subjects
were asked to complete the sex-speciﬁc ques-
tionnaire and return it to an assistant in a
sealed envelope. The subjects were then exam-
ined by a physician who was unaware of their
responses. They reported Pearson correlations
for overall pubertal development of 0.57 for
males and 0.52 for females. The investigators
suggested that the correlations might improve
if adolescents were given the opportunity to
examine their bodies in private prior to
completing the questionnaire.
Like the technique of Duke and colleagues,
the work of Morris and Udry has been tested
in many populations. Hergenroeder et al.
(1999) examined the performance of Morris
and Udry’s drawings in a racially diverse sam-
ple of adolescent females. Overall, they found
very little agreement between the adolescent
self-rating of pubertal development and the
physician assessment. The kappa coefﬁcient for
breast development was higher among African-
American females (κ = 0.42) than among
European-American females (κ = 0.35); how-
ever, for pubic hair distribution, agreement
with the physician was higher among
European Americans (κ = 0.44 vs. κ = 0.26.)
There is some concern that adolescents
with anxiety disorders (e.g., body dysmorphic
syndrome) at the extremes of body size or
those with eating disorders might have diffi-
culty accurately assessing their pubertal devel-
opment. Williams and associates showed both
the Morris and Udry drawings and the Tanner
photographs to a sample of adolescents with
diverse levels of fatness (determined by skinfold
thickness) (Williams et al. 1988). None of the
participants were morbidly obese nor did they
have anorexia. They reported correlations
(Kendall’s ~ τβ) ranging from 0.65 for penis
development to 0.82 for male pubic hair distri-
bution. No significant differences in self-
assessment ability were found with respect to
fatness. In contrast, Bonat and colleagues
tested the Tanner stage line drawings in a
racially diverse sample of children from subur-
ban Maryland, 41% of whom were obese.
Although they found no differences with
respect to pubic hair ratings, they reported that
obese females were more likely than nonobese
females to overestimate their Tanner breast
development stage (0.5 ± 1.1 stages) (Bonat
et al. 2002.) 
Hick and Katzman (1999) evaluated the
use of Morris and Udry’s drawings in a sample
of adolescent females with anorexia nervosa.
The subjects were asked to complete two sepa-
rate sets of forms, one in which they selected
their current level of pubertal development,
and the other in which they indicated their
desired level. For breast development, there
was 30% agreement between the adolescent
rating and that of the physician. The adoles-
cent self-assessment of pubic hair distribution
was more accurate (50% agreement). Female
adolescents with anorexia nervosa tended to
underestimate their breast development and
overestimate their pubic hair distribution. The
majority of the adolescents desired secondary
sex characteristics that were equal to or more
mature than their current Tanner stage. 
Several issues might affect the accuracy of
an adolescent’s self-assessment of pubertal mat-
uration: the adolescent’s actual Tanner stage,
where the instrument is administered (school
vs. clinic setting), and whether he/she is aware
that a physical examination is imminent. To
study these issues, Schlossberger and colleagues
(1992) asked a sample of adolescents from an
urban public middle school to complete
Morris and Udry’s instrument. The students
were unaware that they would later receive a
physical examination. Two months later, the
investigators invited the students to their clinic
for a physical examination, where they were
again asked to complete the self-assessment
instrument. Not surprisingly, they reported
that adolescents were more accurate in their
self-assessment in the clinic setting than they
were in the school setting. Whether this effect
was due to the setting itself or to the knowl-
edge of the impending physical exam is
unknown. In general, adolescents were found
to overestimate their Tanner stage when they
were early in pubertal development and
tended to underestimate their development at
later stages. 
In addition to the photograph and
drawing-based methods of pubertal self-
assessment, several teams of investigators have
developed verbal and written instruments.
These assessment tools are thought to be more
acceptable in a classroom setting, as school
officials might find visual depictions to be
inappropriate (Petersen et al. 1988). Petersen
and colleagues tested their pubertal assessment
interview (puberty development scale; PDS)
on two successive cohorts of middle school stu-
dents who were interviewed twice yearly from
sixth to eighth grade. The internal consistency
of the questions in the interview was high, with
Cronbach alpha coefﬁcients ranging from 0.68
to 0.83. In addition, most of the adolescents’
responses followed the expected pattern, as few
of them experienced regression of their puber-
tal indicators over time. Although the validity
of the PDS was not examined (the students
were not examined by a physician), a different
study reported correlations with physician
assessments in the range of 0.61–0.67 (Brooks-
Gunn et al. 1987).
Several years after the development of the
PDS, Carskadon and Acebo (1993) adapted it
for use on a written questionnaire. The inves-
tigators found the validity of the written adap-
tation of the PDS to be high, with Spearman
correlations ranging from 0.84 and 0.87. The
items on the questionnaire were also internally
consistent, with Cronbach alpha coefficients
ranging from 0.67 to 0.70. 
In an attempt to simplify the assessment of
pubertal development even further, Berg-Kelly
and Erdes (1997) tested the use of a global
question. Adolescents were asked, “Considering
your bodily development, how do you rate
yourself compared to your classmates: very late,
somewhat late, similar to most of your class-
mates, somewhat early, or very early?” Using
this question, they reported a very high concor-
dance with physician assessments: 95% for
males and 93.5% among females.
Overall, many adolescents appear to be
able to provide a reasonably accurate assess-
ment of their pubertal maturation based on
the presence of secondary sex characteristics.
Although the use of Tanner’s SMS pictures
with accompanying written explanations
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self-assessment methods, many of the meth-
ods yield correlations in the range of those
reported for inter-rater agreement of pubertal
assessments conducted by health professionals
(Berg-Kelly and Erdes 1997). It should be
noted, however, that self-assessment instru-
ments are still not ideal for use in population-
based research, as they perform less well in
special populations (e.g., certain racial/ethnic
groups and those with clinical diagnoses such
as anorexia nervosa). Furthermore, measure-
ment of puberty in boys and girls is most
likely associated with error because of differ-
ences between raters, despite training. Still,
this error is unlikely to be systematic (bias)
with respect to potential environmental expo-
sures. The magnitude of this error may vary
with respect to other characteristics of the
population (e.g., chronic disease, socio-
economic status, fatness) but is likely to be a
conservative estimate of effect. However, if
this error is systematic, the potential for bias
arises with respect to pubertal outcomes. To
address this methodologic concern, continued
investigation into sensitive biomarkers is
needed if we are to estimate more precisely
the effect of environmental exposures or other
factors on human fecundity as measured by
the onset and attainment of puberty. As such,
the development of new methods for pubertal
assessment, is urgently needed.
Other Physical Biomarkers 
of Pubertal Development
Skeletal growth. Skeletal growth is one of the
most striking characteristics of puberty. A
commonly used marker of skeletal growth is
linear growth velocity (height increase per
year), and this correlates with the Tanner
stages of sexual development [see Family
Practice Notebook.com (2003a, 2003b) for
further details of male and female Tanner
stages). In females the pubertal growth spurt
starts at Tanner breast stage 2 (the start of
puberty) and peaks at stage 3. Linear-growth
velocity begins to increase in males at genital
stage 3 and pubic-hair stage 2, but peak height
velocity is not attained until Tanner stage 4. 
Body composition. Significant changes in
body composition (body mass index and lean
body mass) also occur during puberty and
show distinct and important gender differ-
ences. Lean body mass, which primarily reﬂects
muscle mass, begins to increase during early
puberty in both boys and girls. As pubertal
stage advances in boys, their body fat mass
increases while the percentage of body fat
decreases. Among girls both body fat mass and
percentage of body fat increases with advancing
pubertal stage (Saetung et al. 2000).
The chief advantages of using height,
weight, and fat mass as biomarkers of pubertal
stage are that the methodology to obtain
the data is noninvasive, socially acceptable,
rapid, and simple to use. Equipment is rela-
tively inexpensive in most cases, and there is a
good selection of commercial products avail-
able for measuring height and body fat
(Healthchecksystems.com 2003).
Fundamental voice frequency. It is well
known that among males the pitch of the
voice, or the fundamental voice frequency,
lowers substantially during puberty. Using
laryngography, Harries and colleagues (1997)
demonstrated that the most abrupt change in
the adolescent male voice occurs during the
transition from Tanner stage 3 to Tanner
stage 4 in pubertal development. Recent
advances in technology have made it possible
to identify changes in fundamental voice fre-
quency by recording adolescents reading stan-
dardized passages of text at regular intervals
(i.e., every 3 months) (Campisi et al. 2002).
Although the technique appears to be less sub-
jective than the various methods of pubertal
self-assessment, additional work is needed to
verify its reliability.
Molecular and Cellular
Biomarkers of Puberty
Secondary sex characteristics determined using
Tanner scales provide a relatively useful meas-
ure of pubertal stage and have formed the
cornerstone of many studies into pubertal
development. However, gross anatomical cate-
gorization is relatively limited in its applicabil-
ity to a large and diverse population and is also
limited in that it only informs on the physio-
logical end point. That is, if puberty-associated
problems exist, then these observational meas-
urements of pubertal stage are usually of little
use in diagnosis and prognosis. If pubertal or
other developmental problems are occurring or
might be expected to occur (given, for exam-
ple, a certain genetic makeup of an individual),
then methods to observe and characterize such
problems at an early (preclinical) stage are
required. Such methods require monitoring
molecular and cellular changes, and accessible
tissues (e.g., urine, blood) are the normal
source of material for such studies. Indeed,
these specimens are used extensively to measure
numerous indicators including chemical, hor-
mone and metabolite levels, the expression lev-
els of genes and proteins, and the integrity of
genetic material (DNA). Characterization of
the normal molecular and cellular changes that
occur in the prepubescent and pubescent body
may offer the best approach to achieve this
aim, and recent studies have uncovered a num-
ber of promising biomarkers of normal and
abnormal pubertal development that may
prove useful in longitudinal human studies.
Genetic markers. One of the main beneﬁts
of postgenomic methodologies and bioinfor-
matics is that they have increased our ability to
identify the genetic factors primarily or partly
responsible for developmental problems. At
least one ongoing longitudinal study (Avon
Longitudinal Study of Parents and Children
2003) has been speciﬁcally designed to deter-
mine ways in which an individual’s genotype
combines with environmental pressures to
influence health and development (Golding
et al. 2001). Such studies enable researchers to
identify genetic biomarkers of susceptibility,
enhancing our ability to diagnose potential
reproductive problems early on and resulting
in the instigation of appropriate preventive
measures. For example, recent work by
Witchel et al. (2001) suggests that in some
cases the development of premature pubarche
(PP) can be associated with the occurrence of
multiple sequence variants at various suscepti-
bility loci, especially steroidogenic enzyme
genes such as cytochrome P45021 (CYP21).
Another steroidogenic enzyme, CYP19 (P450
aromatase), is of central importance in pubertal
development (MacGillivray et al. 1998). The
aromatase enzyme complex catalyzes the con-
version of androgens to estrogens in a wide
variety of tissues. Aromatase deficiency
(reviewed in Bulun 2000) usually results from
autosomal recessive inheritance of mutations in
the CYP19 gene. Females with this condition
have ambiguous genitalia and fail to develop
secondary sexual characteristics. Sexual devel-
opment appears to progress normally in males,
although the pubertal growth spurt and skele-
tal maturation are adversely affected. In con-
trast to the effects observed with CYP19
mutations, certain CYP19 splice variants can
lead to increased extraglandular aromatization,
producing an excess of estradiol that leads to
PP in females and feminization of males
(Stratakis et al. 1998). 
Other genes have also been identiﬁed that
have splice variants, polymorphic variants or
mutations that could serve as possible bio-
markers of susceptibility to precocious or
delayed puberty in one or both sexes.
Mutations in Dax1, for example, have been
associated with PP in males (Domenice et al.
2001). Mutations in type II 3-beta hydroxy-
steroid dehydrogenase have been associated
with PP in girls (Marui et al. 2000). Point
mutations in luteinizing hormone (LH) recep-
tor have been associated with PP in boys
(Cocco et al. 1996), but no effect has been seen
in girls. Thus, identiﬁcation and characteriza-
tion of these and other such biomarkers could
facilitate the development of genetic screens
capable of indicating the likelihood or cause of
abnormal pubertal development.
Biomarkers of bone growth and mineral-
ization. During puberty, bone growth and
mineralization, as well as bone turnover,
increase dramatically. Current data suggest
biochemical markers of bone remodeling may
be useful in the clinical investigation of bone
turnover in children in health and disease.
Mini-Monograph | Rockett et al.
108 VOLUME 112 | NUMBER 1 | January 2004 • Environmental Health Perspectivesvan Coeverden et al. (2002) demonstrated that
bone metabolism markers are good predictors
of bone mass in boys and of bone mass increase
in both sexes. Previously, Sen et al. (2000)
showed that during the male pubertal growth
spurt, there is a relationship between bone
remodeling and increasing serum osteocalcin
and alkaline phosphatase levels. Peak levels
occur when sexual maturation reaches Tanner
stage 4 and are associated with the rapid
growth in height. As sexual maturation reaches
stage 5, levels gradually decrease with growth
maturation, and their levels decline to the level
of adults. Other studies have examined urinary
excretion of speciﬁc bone resorption markers as
a function of adolescent growth stages. In a
prospective longitudinal study of urinary excre-
tion of a bone resorption marker [collagen
type I N-telopeptides (NTx)] in adolescents,
Bollen (2000) found that for both males and
females, the excretion of NTx was correlated
with the changes in growth rate during ado-
lescence. The expression of other collagens,
including procollagen type I C-terminal
propeptide (PICP), the cross-linked C-termi-
nal telopeptide of type I collagen (ICTP),
and procollagen type III N-terminal propep-
tide (P3NP), also demonstrates some correla-
tion with pubertal development (Crofton
et al. 1997).
Hormonal biomarkers of puberty. Puberty
has been deﬁned as 
. . . a maturational process of the hypothalamus-
pituitary-gonadal axis, resulting in growth and
development of the genital organs and, concomi-
tantly, in physical and psychological changes
towards adulthood leading to the capacity to
reproduce. (Delemarre-van de Walle 2002) 
This definition highlights the importance of
the sex steroids and other hormones in the
process and the consequent utility of these hor-
mones as biomarkers of pubertal development. 
Increased secretion of adrenal androgens
occurs in the earliest stages of puberty under
the control of the hypothalamus–pituitary–
adrenal axis. These hormones cause pubic and
armpit hair to develop and sensitize the andro-
gen receptors of the hypothalamus and the
pituitary, eventually leading to the activation
of the HPG axis and the initiation of puberty.
The main hormone involved in the regulation
of puberty is gonadotrophin-releasing hor-
mone (GnRH). Produced in the hypothala-
mus, GnRH stimulates the production and
release of both LH and follicle-stimulating
hormone (FSH) from the pituitary. However,
it is difﬁcult to measure levels of GnRH, as it
secreted into portal circulation and trans-
ported directly to the pituitary. Furthermore,
it has a short half-life of only 4–8 min
(Redding et al. 1973a, 1973b). Thus, the
onset of pubertal development is usually
measured through hormones regulated
directly or indirectly by GnRH, including the
gonadotrophins (LH, FSH) and sex steroid
hormones (testosterone and estrogen). The
onset of puberty sees an increase in the levels of
LH. At ﬁrst this only occurs during the night
and is associated with increases in testosterone
(boys) and estrogen (girls) the following morn-
ing. Because all three of these hormones can be
robustly and inexpensively measured in urine,
these initial increases can be used as early bio-
markers of pubertal onset (Wu et al. 1993). In
addition to the gonadotrophins and sex steroid
hormones, there are a number of other hor-
mones whose regulation and level of expression
appear to be closely linked with pubertal devel-
opment. These include the following:
Mullerian inhibiting substance. Mullerian
inhibiting substance (MIS) (also known as
anti-Mullerian hormone), a gonadal peptide
hormone, is a member of the transforming
growth factor-beta family and an important
factor for male sex differentiation. It is pro-
duced by Sertoli cells from the time of fetal sex
differentiation to puberty and is among the
best characterized of Sertoli cell products, mak-
ing it a good biomarker for the pathophysio-
logical state of such cells. Because of the
thorough characterization of MIS levels, it is
possible that serum MIS could be used to
evaluate pubertal onset. MIS values for males
rise rapidly during the first year of life (uni-
formly measurable in all prepubertal boys), are
highest during late infancy, then gradually
decline until puberty (Lee et al. 1996). In nor-
mal testes the switchoff of MIS expression is
usually associated with the terminal differentia-
tion of Sertoli cells and the appearance of pri-
mary spermatocytes (Rajpert-De Meyts et al.
1999) make it a good candidate for staging
pubertal development in boys. MIS levels cor-
relate better with developmental age than with
chronological age, and males with delayed
puberty have elevated levels. In contrast MIS is
undetectable in most prepubertal female sub-
jects and is expressed in the ovary only until
the end of fetal life. The main drawback with
using MIS as a measure of pubertal develop-
ment is that current assays have only been suc-
cessfully tested on blood serum. Given that
sampling frequency of blood in a large longitu-
dinal study is unlikely to be high enough to
provide a detailed developmental timeline, it
appears that a urine-based assay needs to be
developed if this test is to be seriously consid-
ered for application as a biomarker of pubertal
development. To date there has been only one
published study involving the measurement of
MIS in urine (Hudson et al. 1990), and levels
were found to be 20–140 times less than those
found in serum.
Inhibins. The inhibins are peptides,
mainly of gonadal origin, that suppress FSH
production. Like MIS they offer a potential
measure of reproductive development (see
review by Raivio and Dunkel 2002). This has
been determined through characterization of
their normal expression levels. Inhibin B
expression, for example, is high in infant boys
but declines in concert with the increase in
gonadotrophins, reaching a nadir at 6–10
years of age (Crofton et al. 2002). Byrd et al.
(1998) consequently suggested that inhibin B
could potentially be used as a biomarker in the
diagnosis of cryptorchidism and precocious
puberty. Studies by Brugo-Olmedo et al.
(2001) suggested that serum inhibin B levels
might also be a reliable marker of the presence
of testicular spermatozoa in patients with
nonobstructive azoospermia. If this is con-
ﬁrmed, it could be used as another biomoni-
toring approach to assessing pubertal onset in
boys. In boys between Tanner stages 1 and 2,
serum inhibin B levels again increase but then
plateau. Serum inhibin A levels in human
males are below detection limits, but both
inhibin A and B are measurable in girls.
Inhibin A and B are found at different levels
in girls depending on pubertal stage (Foster
et al. 2000; Sehested et al. 2000), suggesting
that significant changes in serum concentra-
tions of these and other FSH-regulatory pep-
tides accompany the onset and progress of
puberty and should be investigated as possible
alternative staging markers for pubertal devel-
opment. Although inhibins, like MIS, are
promising biomarkers of pubertal develop-
ment, they suffer from the same disadvan-
tage—almost all studies on inhibins have
relied on blood serum as the biological source
material. This is because only inhibin A has
been detected in urine, and then only in preg-
nant women (Wang et al. 1999). 
Leptin. Leptin, an adipocyte hormone
important in regulating energy homeostasis,
interacts with the reproductive axis at multiple
sites, with stimulatory effects at the hypothala-
mus and pituitary, and inhibitory action on the
gonads. Leptin appears to be a pleiotrophic hor-
mone affecting many different tissues in the
body. Evidence is accumulating that it poten-
tially affects the regulation of GnRH and LH
secretion, puberty, pregnancy, and lactation
(reviewed by Brann et al. 2002). Normal leptin
secretion is necessary for normal reproductive
function to proceed, and leptin may be a signal
allowing for the point of initiation of and pro-
gression toward puberty (Mantzoros et al.
1997). Both prepubertal boys and girls show a
progressive increase of leptin levels until Tanner
stage 2. At the initiation of puberty there is a
divergence in serum leptin concentrations
between boys and girls. In boys, concentrations
increase and then markedly decrease to pre-
pubertal concentration levels. In girls, however,
levels continue to increase (Roemmich and
Rogol 1999). Although leptin thus appears to
offer a possible biomarker of pubertal onset and
development, further studies are ﬁrst required
to clarify its role and relationship.
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sible target for biomarker investigation in
adolescent males is antisperm autoantibodies
(ASA). Although few human studies have
been conducted in this area, it appears that
prepubertal presence of ASA often occurs
among patients with urogenital pathology.
For example, Kurpisz et al. (1996) found sig-
niﬁcant antibody activity to human sperm in
sera samples from prepubertal boys with tes-
ticular failures (cryptorchid or mobile testis).
Of 26 ASA-positive boys examined by Sinisi
et al. (1997), 24 had genital tract abnormali-
ties (cryptorchidism, testicular torsion,
hypospadias), and two had leukemia with tes-
ticular infiltration. However, genital tract
abnormalities do not always lead to the pro-
duction of ASA. In a study of 159 prepubertal
boys suffering from various testicular patholo-
gies, Lenzi et al. (1991) found only 21% of
the patients’ sera showed antibody activity
against antigens on the sperm of healthy fer-
tile donors. The presence of serum antisperm
antibodies is normally considered problem-
atic, as it is a good indicator that fertility will
be or is compromised. Indeed, Check et al.
(2002) suggested that this test be performed
as part of routine semen analysis. However,
we retain a poor understanding of the proﬁle
of ASA that leads to antibody-mediated male
infertility, thus warranting further studies into
this area.
Spermaturia. The evaluation of sperm in
urine (spermaturia) has been used previously
to assess the age of onset of spermarche.
Spermatogenesis can begin before any other
signs of puberty (Nysom et al. 1994). This
conclusion was obtained from spermaturia
studies in two normal boys with testicular vol-
umes of 3 mL and no other signs of puberty
and indicates that the definition of start of
puberty as testicular volumes of 4 mL or more
may be too rigorous. Mol et al. (2002) discov-
ered highly significant associations between
spermaturia and both Tanner stage and
testicular size, hence supporting the validity
of spermaturia as a useful indicator of
puberty. They did, however, ﬁnd that a sub-
stantial rate of false negatives are likely to be
included using this method. Spermaturia is a
more common and regular event during early
and midpuberty than in more mature sub-
jects, but one problem preventing its regular
use as an indicator of puberty is the intermit-
tent occurrence of sperm-negative urine sam-
ples. The incorporation of spermaturia as a
test for puberty in a large sample group would
give this test more power to determine the
distribution of the age of onset. Research is
needed to develop a practical approach for
doing this. Conceptually, it should be possi-
ble to develop a home urine collection system
that would include a ﬁlter upon which sperm
would be trapped. The system could be used
at regular intervals and the filters saved for
later extraction and identiﬁcation of sperm.
Specimen Collection 
There are many molecular and cellular
biomarkers that can potentially be used to
measure pubertal development. However, it is
also clear that the nature of these markers is
such that biospecimens must be obtained from
study participants. Biospecimen collection is
thus one of the main issues to consider in
determining the molecular and cellular bio-
markers that can be measured in a study. The
use of biospecimens in an epidemiologic study,
although often necessary, can be confounded
by many different events. For example, sample
harvest timing and procedures, as well as stor-
age and extraction protocols, may affect the
expression or integrity of some biomarkers,
particularly those that are cellular or molecular
in nature. Furthermore, the level of certain bio-
markers, such as serum hormones, may natu-
rally ﬂuctuate on a daily or even hourly basis.
Time is also a factor when measuring certain
analytes in blood and urine. Because of in-
stability, some analytes must be measured
within a few hours of collection if the measure-
ment is to be useable. In addition, the appro-
priate use of preservatives, storage media, and
storage and transportation temperatures must
also be considered. Sampling procedures must
therefore be planned and conducted to reduce
the variation that can arise from the use of dif-
ferent protocols. This will require the develop-
ment of standardized protocols for collection,
storage, and transportation of samples. For
example, samples might be obtained during
school hours under appropriate medical super-
vision and with parental approval. This would
save travel to the clinic by parents accompany-
ing their child and enable study workers to
access large groups of children at about the
same time of day. Another approach is to
develop methods for home collection of
biospecimens (Rockett et al. 2004).
Where indicators of puberty are being
measured, it is clear that the entire cohort will
comprise (pre-) adolescents in varying stages
of development. As such, study participation
and compliance with specimen collection are
key issues underlying the success of such a
study. This necessitates the identification of
biomarkers that can be derived through non-
invasive methods such as anatomical measure-
ments or readily accessible biospecimens such
as urine, saliva, and blood. Many robust
methods are already available, such as the
measurement of urinary hormones (Lasley
et al. 1994) or DNA analysis from buccal cells
(Lum and Marchand 1998). An emerging
paradigm for biomonitoring studies in
children is the use of surrogate tissue analysis
(STA) (Rockett 2002; Rockett et al. 2002).
This approach has yet to be veriﬁed but may
prove useful in 5–10 years’ time. In the STA
approach an easily obtained tissue (i.e.,
biospecimen) is used to provide information
about an inaccessible target tissue. For exam-
ple, one might examine gene or protein
expression in a patient’s peripheral blood
lymphocytes to determine if there is altered
development or function in their uterus
(Reddy et al. 2001; Rockett et al. 2002).
Much work is still required to verify this
approach, but many see it as a valid and
useful new paradigm.
Conclusions
Over the past 15 years or so, there has been a
surging interest in children’s health and devel-
opment. This has led to the formation and
increasing expansion of a pediatric research
network (American Academy of Pediatrics
2003) and the instigation of a large number of
longitudinal and cross-sectional cohort studies:
the Northern California Childhood Leukemia
study, 1995–2003 (2003); the U.S.–Mexico
Border Children’s Pesticide Exposure study,
1996–2004 (2003); the Minnesota Children’s
Pesticide Exposure study, 1997–present
(2003); the NCS, 2000–present (2003);
and the National Health and Nutrition
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Table 1. Summary of biomarkers for assessing
pubertal onset and progression in males.
Biomarker of  Biomarker of 
pubertal onset pubertal progression
Body composition Body composition
Bone metabolism markers
Bone resorption markers
Fundamental voice 
frequency
FSH
Inhibin B Inhibin B
Leptin Leptin
LH
MIS
Pubic hair type and extent Pubic hair type and extent
Penis size Penis size
Skeletal growth rate
Spermaturia
Testis size  Testis size
Testosterone Testosterone
Table 2. Summary of biomarkers for assessing
pubertal onset and progression in females.
Biomarker of  Biomarker of 
pubertal onset pubertal progression
Body composition Body composition
Bone resorption markers Bone resorption markers
Estrogen Estrogen
FSH FSH
Inhibin A
Inhibin B Inhibin B
Leptin Leptin
LH LH
Menarche
Pubic hair type and extent Pubic hair type and extent
Skeletal growth rate Skeletal growth rate
Thelarche ThelarcheExamination Survey (2003). Data from these
research centers and studies have provided
increasing evidence for links between environ-
mental exposures and pubertal development
(e.g., blood lead and alterations in pubertal
development in girls (Seleven et al. 2003;
Wu et al. 2003). It is likely that over the next
20 years or so we will see a shift toward even
more intense monitoring of child health,
especially as the high-profile NCS gains
momentum and begins to generate data. 
Puberty is the most dramatic process in
child development. Unfortunately, the multi-
ple characteristics of puberty have made it difﬁ-
cult to determine an all-encompassing
definition in terms of the biochemical and
physiological changes that occur. Defining
puberty has also been confounded by the secu-
lar trend in growth. Although most agree that
puberty is the time at which onset of sexual
maturation occurs, there are clearly various
biomarkers (anatomical and biochemical) that
can be used to define this onset (Tables 1
and 2). Puberty also occurs at different rates
and in different orders in different people,
depending on genetic and environmental com-
ponents. For example, in African-American
girls, pubic hair, on average, seems to appear
slightly ahead of breast development. In con-
trast the ﬁrst manifestation of puberty in white
girls is usually breast development. Thus, an
accurate clinical deﬁnition of puberty must be
developed that acknowledges any of the various
biomarkers that can appear ﬁrst. This need not
be speciﬁc but might include the appearance of
any one or small number of carefully selected
biochemical and/or anatomical biomarkers. In
many cases these will be different between
males and females, as they are physiologically
distinct in many respects. Identification and
veriﬁcation of such biomarkers across the span
of human diversity can only be determined
through the longitudinal study of large cohorts.
We are still far from completely under-
standing most normal development processes
and the bounds within which “normality” falls.
Thus, before we can understand a disease
processes, we must ﬁrst determine what consti-
tutes normal pubertal development in today’s
society, namely, what is an acceptable range for
normal development and what constitutes
developmental “unevenness” versus pathology.
This educational process, encompassing labora-
tory research and human epidemiologic stud-
ies, should reveal new biomarkers that are both
robust and sensitive. 
In some cases it seems unlikely that cur-
rent biomarkers of reproductive development
and health will be displaced, at least in the
near to mid-future. For example, the use of
Tanner staging is a simple and inexpensive
method of assessing pubertal development.
Though it has its faults, such as being a sub-
jective method, it is probably still the best
choice for use in large longitudinal cohort
studies such as the NCS. However, given the
multiple and extensive biochemical and
anatomical changes that occur during puberty,
it is highly likely that molecular and cellular
markers, which can be measured without sub-
jectivity, will play an increasingly important
role in assessing pubertal development. Only a
few such biomarkers are known today, but it
seems likely that many more are awaiting dis-
covery and characterization. It is our expectation
that at least some of these will enable health care
professionals to better follow the pubertal
process in future generations of children and
ultimately pave the way for new approaches in
disease identiﬁcation and management.
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